Perindopril + Moxonidine

Perindopril + moxonidine is a combination antihypertensive therapy that pairs two medications with complementary mechanisms of action for treating hypertension (high blood pressure). ## Drug Information: Perindopril + Moxonidine ### Perindopril Component Perindopril is an angiotensin-converting enzyme (ACE) inhibitor that works by blocking the formation of angiotensin II, a hormone that causes blood vessels to constrict. By inhibiting this process, perindopril helps blood vessels relax, which lowers blood pressure and reduces the workload on the heart[3][4][9]. Perindopril demonstrates good tissue penetration, strong affinity for ACE, and a long duration of action, supporting its dose-dependent blood pressure lowering efficacy[3]. It's available in tablet form in various strengths (2 mg, 4 mg, and 8 mg)[9]. ### Moxonidine Component Moxonidine is a newer-generation centrally acting antihypertensive drug that primarily targets imidazoline receptor subtype 1 (I1) and, to a lesser extent, alpha-2-adrenoreceptors in the rostral ventrolateral medulla (RVLM) of the brain[2][6][8]. This selective binding profile distinguishes it from older centrally-acting antihypertensives like clonidine, which have stronger effects on alpha-2 receptors and consequently more side effects[8]. By activating these receptors, moxonidine reduces sympathetic nervous system activity, which leads to decreased systemic vascular resistance and lower blood pressure[2][6]. It's typically administered in doses between 0.2 and 0.4 mg per day[8]. ### Combination Benefits The combination of perindopril and moxonidine appears to be studied for its potential angioprotective effects in hypertensive patients with metabolic syndrome[1]. This combination leverages the complementary mechanisms of both drugs: 1. Perindopril works peripherally by inhibiting the renin-angiotensin-aldosterone system 2. Moxonidine works centrally by reducing sympathetic nervous system activity This dual approach may provide more comprehensive blood pressure control while potentially offering additional benefits for patients with metabolic complications. ### Clinical Considerations Moxonidine has been shown to reduce left ventricular hypertrophy and may have favorable effects on insulin resistance[8]. It's generally well-tolerated with fewer central side effects than older centrally-acting antihypertensives, though it may cause dry mouth, dizziness, headache, fatigue, and nausea[6]. Perindopril has demonstrated cardiovascular protective effects beyond blood pressure reduction, including improvements in arterial stiffness and endothelial function[3]. When used in fixed-dose combinations with other agents like amlodipine or indapamide, perindopril has shown significant reductions in cardiovascular events and mortality[3][5][7]. The specific combination of perindopril and moxonidine may be particularly beneficial for hypertensive patients with metabolic syndrome, as indicated by ongoing clinical research[1].